Search research articles
Contact Us
Filters
Showing results (211-220 of 233) with videos related to
Page
of 24
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
August 17, 2000
Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo
A Bond, N M Jones, C A Hicks, et al.
Journal of Medicinal Chemistry
|
July 21, 1998
Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists
H Zarrinmayeh, A M Nunes, P L Ornstein, et al.
Cephalalgia : an International Journal of Headache
|
June 16, 2004
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine
C N Sang, N M Ramadan, R G Wallihan, et al.
Nature Neuroscience
|
June 25, 2002
Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures
Ilse Smolders, Zuner A Bortolotto, Vernon R J Clarke, et al.
Pharmacology, Biochemistry, and Behavior
|
March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects
J M Witkin, J A Monn, J Li, et al.
Nature
|
December 2, 1999
Kainate receptors are involved in synaptic plasticity
Z A Bortolotto, V R Clarke, C M Delany, et al.
Nature
|
October 23, 1997
A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission
V R Clarke, B A Ballyk, K H Hoo, et al.
Journal of Medicinal Chemistry
|
November 23, 2000
Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic acid (AMPA) receptors
P L Ornstein, D M Zimmerman, M B Arnold, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 20, 2005
Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives
Matthew J Fisher, Ryan T Backer, Iván Collado, et al.
Neuropharmacology
|
January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 233) with videos related to
Sort By:
Page
of 24
The Journal of Pharmacology and Experimental Therapeutics
|
August 17, 2000
Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo
A Bond, N M Jones, C A Hicks, et al.
Journal of Medicinal Chemistry
|
July 21, 1998
Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists
H Zarrinmayeh, A M Nunes, P L Ornstein, et al.
Cephalalgia : an International Journal of Headache
|
June 16, 2004
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine
C N Sang, N M Ramadan, R G Wallihan, et al.
Nature Neuroscience
|
June 25, 2002
Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures
Ilse Smolders, Zuner A Bortolotto, Vernon R J Clarke, et al.
Pharmacology, Biochemistry, and Behavior
|
March 13, 2017
Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects
J M Witkin, J A Monn, J Li, et al.
Nature
|
December 2, 1999
Kainate receptors are involved in synaptic plasticity
Z A Bortolotto, V R Clarke, C M Delany, et al.
Nature
|
October 23, 1997
A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission
V R Clarke, B A Ballyk, K H Hoo, et al.
Journal of Medicinal Chemistry
|
November 23, 2000
Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic acid (AMPA) receptors
P L Ornstein, D M Zimmerman, M B Arnold, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 20, 2005
Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives
Matthew J Fisher, Ryan T Backer, Iván Collado, et al.
Neuropharmacology
|
January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist
Jeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.
Page
of 24